Codexis appoints Raymond De Vré to Board; adopts amended bylaws

CODEXIS, INC.

Raymond De Vré appointed as Class I director effective Nov 7, 2024; term expires at 2026 annual meeting.
De Vré, former CEO of PolyPeptide Group and ex-McKinsey partner, joins Science and Technology Committee.
Initial RSU grant of $200,000 (47,847 shares at $4.18 close); annual cash retainer $50,000 plus $10,000 committee retainer.
Bylaws amended to align with Delaware law, update stockholder nomination/proposal procedures, and meeting conduct rules.
No material financial impact; routine governance changes.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Raymond De Vré

Class I director

CDXS · CODEXIS, INC.

Effective: 2024-11-07
Filed: November 12, 2024, 6:59 PM ET

appointed Raymond De Vré as a member of the Board as a Class I director, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Raymond De Vré was appointed as Class I director at CODEXIS, INC..

Action: appointed
Role: Class I director

Exact text from the filing

appointed Raymond De Vré as a member of the Board as a Class I director, effective immediately.

View on SEC.gov

CODEXIS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-255904

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.